Synairgen Share Discussion Threads

[stoneme] 08/9/2020 08:16

Are you the village idiot ?

[jackjackpaul] 08/9/2020 08:16

nice shake but cannot buy

[tickboo] 08/9/2020 08:08

Indeed they had fewer patients than planned but the main thing is safety which further supports COVID and given the infection rate is on the up it can only strengthen SNG001 as a therapy. I imagine the US, Brazil and India may make a decision before the U.K.

[mirako] 08/9/2020 08:05

Looking at this more carefully, it seems like the issue from asthma trials repeated itself: not enough patients exacerbated and so there were no significant treatment effects.

There were some effects on the patients who had already exacerbated although not enough to meet endpoints. That's not terribly surprising, though, since only 32% of 109 patients were exacerbating, i.e. n=35 or so.

The logical next step for COPD might be another P2 in exacerbating patients with a confirmed viral infection. Marsden's quote implies as much when he says "SNG001 could be a valuable novel therapeutic for exacerbating COPD patients". The potential value of this drug is less than one that prevents exacerbations, however.

Looking on the bright side, this is somewhat supportive of the Covid-19 use case for hospitalised patients to speed recovery and prevent progress to ventilation.

[jackjackpaul] 08/9/2020 08:00

#SNG - Flu season coming up - Covid cases surging across the globe - this is the perfect storm for Synairgens’ SNG001.

There’s a very strong chance that SNG001 will be the 6th drug to be granted EUA for use against C-19 – and possibly the first drug to be given full approvals.

[tburns] 08/9/2020 07:59

I think this will most likely fall over the day the close around £1.70-1.75 today. Still a great long term hold but short tern fluctuations to be expected off that RNS. Those on t10 and T20 trades will probably close early doors. GLA

[investordave] 08/9/2020 07:58

You're so smart....